Intensity Therapeutics Inc. (NASDAQ:INTS) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Intensity Therapeutics Inc. (NASDAQ:INTS) have been given an average recommendation of “Moderate Buy” by the four ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $37.50.

A number of research analysts have commented on the company. Weiss Ratings downgraded Intensity Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, April 24th. Freedom Capital raised Intensity Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 30th. Benchmark reiterated a “speculative buy” rating on shares of Intensity Therapeutics in a report on Wednesday, May 20th. Finally, Wall Street Zen raised Intensity Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, April 4th.

Intensity Therapeutics Stock Up 1.2%

INTS stock opened at $4.90 on Friday. The company has a 50 day moving average of $4.35 and a two-hundred day moving average of $6.37. The company has a market cap of $13.23 million, a price-to-earnings ratio of -0.86 and a beta of 2.78. Intensity Therapeutics has a 12-month low of $3.51 and a 12-month high of $43.50. The company has a quick ratio of 4.86, a current ratio of 4.86 and a debt-to-equity ratio of 0.01.

Intensity Therapeutics (NASDAQ:INTS) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.96) EPS for the quarter, beating the consensus estimate of ($1.08) by $0.12. On average, equities analysts anticipate that Intensity Therapeutics will post -2.7 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Jane Street Group LLC bought a new position in Intensity Therapeutics during the fourth quarter valued at about $26,000. Corient Private Wealth LLC bought a new position in shares of Intensity Therapeutics in the 4th quarter valued at approximately $41,000. State Street Corp lifted its holdings in Intensity Therapeutics by 839.3% in the 4th quarter. State Street Corp now owns 136,200 shares of the company’s stock worth $56,000 after purchasing an additional 121,700 shares during the last quarter. Legacy Advisors LLC bought a new stake in Intensity Therapeutics during the fourth quarter worth approximately $63,000. Finally, Mesirow Financial Investment Management Inc. grew its holdings in Intensity Therapeutics by 25.5% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock valued at $103,000 after purchasing an additional 51,000 shares during the last quarter. Institutional investors own 3.74% of the company’s stock.

About Intensity Therapeutics

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.